Tretinoin and Tadalafil Interaction: What Patients and Clinicians Need to Know

Does Tretinoin Interact With Tadalafil?

No clinically meaningful interaction exists between topical tretinoin and tadalafil. The two drugs act through entirely different mechanisms, are distributed to different tissue compartments, and share no overlapping metabolic pathway at therapeutic doses. Patients prescribed topical tretinoin for acne or photoaging who also take tadalafil for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), or pulmonary arterial hypertension (PAH) do not require dose modification for either drug.

Why the Interaction Risk Is Essentially Zero

Topical tretinoin (0.025%, 0.1% cream, gel, or microsphere formulation) is applied to skin, where roughly 1 to 2% of the dose crosses the stratum corneum into systemic circulation [1]. That minute plasma concentration, typically well below 1 ng/mL in adults using standard facial application, is too low to trigger any meaningful CYP enzyme induction or inhibition [2].

Tadalafil is metabolized almost exclusively by hepatic CYP3A4 [3]. A drug must achieve sufficient plasma concentration and bind CYP3A4 with meaningful affinity before it can shift tadalafil exposure. Topical tretinoin meets neither criterion at normal use.

Comparing the Two Drugs Side by Side

| Parameter | Topical Tretinoin | Tadalafil | |---|---|---| | Drug class | Retinoid (vitamin A derivative) | PDE5 inhibitor | | Route | Topical (skin) | Oral | | Primary metabolism | Local skin oxidation; minimal CYP involvement at topical doses | Hepatic CYP3A4 | | Systemic bioavailability | ~1 to 2% | ~80% (oral) [3] | | Half-life | N/A (topical; minimal systemic) | ~17.5 hours [3] | | Blood pressure effect | None | Moderate vasodilation; mean -8.4 mmHg systolic [3] | | Contraindicated with | Waxing, abrasive agents (skin), oral retinoids | Nitrates, riociguat, severe hepatic impairment |

How Tadalafil Works and Where Interaction Risk Actually Lives

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. Blocking PDE5 sustains cGMP, relaxing vascular smooth muscle and lowering blood pressure [3]. This vasodilation is the source of tadalafil's real drug interaction risk.

The Nitrate Contraindication

The FDA label for tadalafil carries a boxed-level warning against co-administration with any form of nitrate, including nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate [3]. Nitrates also raise cGMP through a nitric oxide pathway, so combining them with a PDE5 inhibitor can drop systolic blood pressure by 30 mmHg or more, a potentially life-threatening drop [4].

The Physicians' Desk Reference and the 2018 American College of Cardiology/American Heart Association guideline on the management of adults with congenital heart disease note: "PDE5 inhibitors are contraindicated in patients receiving nitrates in any form" [5]. Tretinoin has no connection to this mechanism.

The Alpha-Blocker Caution

Alpha-adrenergic blockers (tamsulosin, doxazosin, alfuzosin) used in BPH can produce additive hypotension with tadalafil [3]. Again, topical tretinoin is not part of this pharmacodynamic equation.

CYP3A4 Inhibitors That Genuinely Matter

Drugs that do raise tadalafil plasma exposure by inhibiting CYP3A4 include ketoconazole, ritonavir, and clarithromycin [3]. A single-dose study showed that ketoconazole 400 mg daily increased tadalafil AUC by 312% [3]. Topical tretinoin does not replicate this effect. The FDA label lists no retinoid as a CYP3A4-relevant inhibitor or inducer [2].

Tretinoin Pharmacology: Why Topical Differs From Systemic

Appreciating the distinction between topical and systemic tretinoin is important for correctly assessing any drug interaction.

Topical Tretinoin Absorption

Tretinoin (all-trans retinoic acid, ATRA) binds nuclear retinoic acid receptors (RARs) to regulate keratinocyte differentiation and collagen synthesis [2]. Applied topically, it stays largely in the epidermis and upper dermis. A 1992 pharmacokinetic study published in the Journal of the American Academy of Dermatology found that plasma tretinoin levels after topical application were within the endogenous range (0.5 to 3.4 ng/mL), meaning the body's own baseline retinol metabolism accounts for most circulating retinoic acid already present [1].

Because the plasma concentration added by topical application is indistinguishable from endogenous levels, no meaningful CYP modulation occurs [2].

Oral / IV Tretinoin Is a Different Story

Systemic ATRA, used at 45 mg/m² per day for acute promyelocytic leukemia (APL), achieves plasma concentrations orders of magnitude higher than topical use. At those concentrations, ATRA induces CYP2C8 and CYP3A4 and can alter the exposure of co-administered drugs [6]. A patient receiving systemic ATRA chemotherapy who is also taking tadalafil for PAH would warrant pharmacist review, because CYP3A4 induction could reduce tadalafil AUC.

That scenario does not apply to standard dermatology or telehealth prescriptions of tretinoin cream or gel.

Tadalafil Pharmacology and Indications

Tadalafil is FDA-approved under three brand names at different doses for different indications [3]:

• Cialis (as-needed 10 mg or 20 mg, or daily 2.5 mg/5 mg) for ED and BPH
• Adcirca (40 mg daily) for PAH
• Alyq (40 mg daily) for PAH (generic equivalent)

Cardiovascular Screening Before Tadalafil

The Princeton Consensus Panel's third iteration, published in the Journal of Sexual Medicine, recommends cardiovascular risk stratification before prescribing any PDE5 inhibitor [7]. Low-risk patients (controlled hypertension, asymptomatic with <3 cardiovascular risk factors, NYHA class I) can start tadalafil without further cardiac testing. Intermediate or high-risk patients need cardiology evaluation first [7]. This risk assessment is entirely independent of tretinoin use.

Tadalafil Pharmacokinetics Summary

After oral dosing, tadalafil reaches peak plasma concentration (Cmax) in approximately 2 hours. Food does not significantly affect its absorption. With a half-life near 17.5 hours, the drug produces detectable PDE5 inhibition for up to 36 hours, which is why it is marketed as "the weekend pill" for on-demand dosing. Steady-state plasma levels with once-daily dosing are achieved within 5 days [3].

Hepatic CYP3A4 converts tadalafil to a catechol metabolite that is further conjugated to a glucuronide and excreted in feces (61%) and urine (36%) [3].

Oral Retinoids and PDE5 Inhibitors: Is There Any Signal?

No published randomized controlled trial, observational study, or pharmacovigilance report through January 2025 documents a clinically significant pharmacokinetic or pharmacodynamic interaction between any topical retinoid (tretinoin, adapalene, tazarotene) and any PDE5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil) [8].

The FDA Adverse Event Reporting System (FAERS) database, searchable at the FDA website, contains no signal for this combination [9].

The HealthRX clinical team reviewed interaction databases including Lexicomp, Micromedex, and the Liverpool Drug Interaction Checker as of January 2025. All three returned a "no interaction found" result for the combination of topical tretinoin with tadalafil. This framework for assessing retinoid-PDE5 inhibitor pairs can be generalized: unless the retinoid is systemic (oral ATRA or acitretin), absorption is too low to modulate the CYP3A4-dependent metabolism that governs PDE5 inhibitor exposure.

Patient Counseling Points

Patients who ask their prescriber or pharmacist about combining topical tretinoin with tadalafil deserve a clear, complete answer rather than a vague "check with your doctor." These are the practical points to cover.

For Tretinoin Users Starting Tadalafil

• No change to your tretinoin application schedule or formulation is needed.
• Tretinoin does not affect how tadalafil is absorbed or cleared.
• Continue applying tretinoin nightly (or as directed) to clean, dry skin.
• Use a non-comedogenic moisturizer and broad-spectrum SPF 30+ sunscreen every morning, since tretinoin increases photosensitivity [2].
• Report significant skin irritation (burning, peeling, erythema) to your dermatology provider; this is a tretinoin-specific adverse effect and is unrelated to tadalafil.

For Tadalafil Users Starting Tretinoin

• Tadalafil does not alter skin absorption of tretinoin or worsen its side-effect profile.
• Do not use tretinoin near the eyes, mouth, or mucous membranes.
• Start with the lowest available concentration (0.025% cream) and increase every 8 to 12 weeks based on tolerance.
• Inform your prescriber about all medications, because tadalafil's real drug interaction risks (nitrates, alpha-blockers, strong CYP3A4 inhibitors) are unrelated to your skin regimen but still need to be screened [3].

Medications That Actually Require Caution With Tadalafil

Patients should receive explicit counseling about drugs that do pose interaction risk with tadalafil. The most clinically significant ones include [3] [4] [5]:

• Nitrates (nitroglycerin, isosorbide): Absolute contraindication. Risk of severe hypotension.
• Riociguat (Adempas): Absolute contraindication per FDA label. Combined PDE5/sGC stimulation causes dangerous hypotension [3].
• Alpha-blockers (tamsulosin, doxazosin): Use with caution; initiate tadalafil at 5 mg if adding to established alpha-blocker therapy.
• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): Reduce tadalafil dose to 10 mg no more than once every 72 hours per FDA labeling [3].
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May reduce tadalafil exposure substantially; dosage increases are generally not recommended due to unpredictability [3].
• Alcohol (more than 5 units): Additive vasodilation and hypotension risk [3].

Special Populations

Patients With Renal Impairment

For ED, tadalafil 5 mg once daily is the recommended starting dose in patients with creatinine clearance 31 to 50 mL/min; once-daily dosing is not recommended if CrCl is <30 mL/min [3]. Topical tretinoin needs no renal adjustment.

Patients With Hepatic Impairment

Mild to moderate hepatic impairment (Child-Pugh A or B): tadalafil should not exceed 10 mg for as-needed dosing [3]. Severe impairment (Child-Pugh C): tadalafil is contraindicated. Systemic ATRA, by contrast, requires hepatic monitoring because elevated transaminases affect ATRA metabolism [6]; this does not apply to topical tretinoin.

Older Adults

Tretinoin may cause more pronounced irritation in older adults with thinner, drier skin; starting at 0.025% and using a thick emollient buffer before application reduces this risk [2]. Tadalafil clearance is mildly prolonged in adults over 65, but the FDA label does not mandate dose reduction on age alone [3]. Cardiovascular comorbidity screening before tadalafil is especially important in this age group per the Princeton Consensus [7].

Patients on TRT (Testosterone Replacement Therapy)

Many patients in telehealth settings use tretinoin for skin quality while also taking tadalafil and testosterone. Testosterone itself is a mild CYP3A4 substrate but does not substantively alter tadalafil exposure at physiologic replacement doses. A 2016 review in the Journal of Sexual Medicine found no pharmacokinetic interaction between testosterone replacement and PDE5 inhibitors in hypogonadal men [10]. No additional dose adjustment is needed for the tretinoin-tadalafil pair in this context.

Tretinoin Drug Interactions Worth Knowing About (Beyond Tadalafil)

Since patients often search for "tretinoin drug interactions" broadly, a brief review of actual tretinoin interaction risks is clinically useful.

Topical Irritants and Keratolytics

Benzoyl peroxide, salicylic acid, sulfur-based products, and alcohol-based toners can cause significant additive skin irritation when layered with tretinoin [2]. This is the most common adverse interaction seen in practice. The FDA labeling advises avoiding "preparations with a strong drying effect" [2].

Photosensitizing Drugs

Tetracycline antibiotics (doxycycline, minocycline), fluoroquinolones, and thiazide diuretics increase photosensitivity on their own. Combined with tretinoin-induced photosensitivity, sun exposure can cause pronounced erythema and increased sunburn risk [2]. Patients should be counseled on consistent sunscreen use whenever these agents are combined.

Oral Vitamin A Supplements

Taking high-dose vitamin A supplements (>5,000 IU/day) alongside any retinoid risks additive hypervitaminosis A effects, particularly with oral retinoids such as isotretinoin [2]. With topical tretinoin the systemic risk is lower but still worth monitoring.

Waxing and Physical Procedures

The FDA label for tretinoin warns against waxing, chemical depilatories, and dermabrasion on tretinoin-treated skin due to risk of skin fragility and scarring [2].

When to Consult a Prescriber

No interaction between topical tretinoin and tadalafil requires urgent action. Contact a clinician if you experience any of the following, because these symptoms could reflect tadalafil-specific adverse effects or an underlying cardiovascular issue unrelated to tretinoin:

• Sudden vision loss or changes in color vision (possible non-arteritic anterior ischemic optic neuropathy, NAION)
• Sudden hearing loss or tinnitus
• Chest pain, dizziness, or syncope after taking tadalafil
• Priapism (erection lasting more than 4 hours)
• Severe or sudden hypotension

These adverse effects are listed in tadalafil's prescribing information and occur independently of any retinoid use [3].